Press Releases
IGEM Therapeutics appoints Dr David Chiswell as a Non-Executive Chairman
Cambridge Antibody Technology co-founder and CEO, Dr Chiswell brings 30 years of biotechnology experience to IGEM’s Board London, 9 April 2019 – IGEM Therapeutics...
Read moreIGEM Therapeutics announces further UK government funding to develop novel IgE antibody targeting solid tumours expressing HER2
Company receives grant from Innovate UK Biomedical Catalyst Primer Award London, 2 April 2019 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel...
Read moreIGEM Therapeutics announces final close of £5 million Series A financing round
New investors Alsa Holdings and UCL Technology Fund join Epidarex Capital Proceeds will allow IGEM to continue development of IgE therapeutic antibody portfolio and...
Read moreIGEM Therapeutics awarded “Best Start-up Biotech Company” at the 2018 OBN Awards
London, 12 October 2018 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced...
Read moreIGEM Therapeutics shortlisted as a finalist in the “Best Start-up Biotech Company”
IGEM Therapeutics shortlisted as a finalist in the “Best Start-up Biotech Company” category of the 2018 OBN Awards London, 22 August 2018– IGEM Therapeutics (IGEM)...
Read moreIGEM Therapeutics announces UK government funding to develop a novel IgE antibody targeting solid tumours
£1.45 million grant from Innovate UK Biomedical Catalyst Funds enable IGEM to progress second product candidate towards the clinic London, 9 May 2018 – IGEM...
Read moreIONTAS and IGEM Therapeutics collaborate to identify novel IgE antibodies for cancer targets
Cambridge, UK, 04 April 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced today that it will collaborate...
Read more£2 million raised from Epidarex Capital
Raises £2 million from Epidarex Capital to progress pipeline of IgE antibody drug candidates to treat cancer
Read more